Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a global leader in precision genetic medicine for rare diseases, announced on November 29, 2024, the granting of equity awards to 14 new employees who…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company set to rebrand as BeOne Medicines, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination…
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced that China’s National Healthcare Security Administration (NHSA) has updated its 2024 National Reimbursement Drug List (NRDL) to include several of the company’s…
Exelixis, Inc. (Nasdaq: EXEL) announced that the U.S. Food and Drug Administration (FDA) has scheduled a discussion of the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) at an Oncologic…
Foresight Diagnostics (Foresight) today revealed new data from its ultra-sensitive Foresight CLARITY™ minimal residual disease (MRD) platform in early-stage breast cancer, which will be presented at the 2024 San Antonio…
Vaxxas, a clinical-stage biotech company, has broadened its global intellectual property portfolio to include 42 patents, reinforcing its exclusive rights to manufacture and sell its proprietary high-density microarray patch (HD-MAP)…
The Children’s Inn at the National Institutes of Health (NIH) has announced that Gilead Sciences Inc. has awarded a $1 million grant to support its ongoing renovation and expansion efforts.…
GE HealthCare (Nasdaq: GEHC) has introduced new clinical applications to its OEC 3D mobile CBCT C-arm portfolio, designed to enhance precise and efficient imaging during endoscopic bronchoscopy procedures in interventional…
Aptar Digital Health, a global leader in digital health solutions, has announced a partnership with the Quality of Life (QoL) technologies lab at the University of Geneva, Switzerland, to enhance…
Alloy Therapeutics Inc., a biotechnology ecosystem company focused on democratizing access to advanced drug discovery technologies, has announced a strategic collaboration and licensing agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK).…
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has announced the launch of its ALISCA™-Breast1 Phase II trial (PUMA-ALI-1201; NCT06369285). The study will evaluate alisertib, in combination with endocrine therapy,…
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a leader in genomic medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application for its…